Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Modification of drug dosages in renal disease.

The Journal of the Oklahoma State Medical Association

Whitsett TL.
PMID: 5014631
J Okla State Med Assoc. 1972 Apr;65(4):129-33.

No abstract available.

Cite
Whitsett TL. Modification of drug dosages in renal disease. J Okla State Med Assoc. 1972;65(4):129-33
Whitsett, T. L. (1972). Modification of drug dosages in renal disease. The Journal of the Oklahoma State Medical Association, 65(4), 129-33.
Whitsett, T L. "Modification of drug dosages in renal disease." The Journal of the Oklahoma State Medical Association vol. 65,4 (1972): 129-33.
Whitsett TL. Modification of drug dosages in renal disease. J Okla State Med Assoc. 1972 Apr;65(4):129-33. PMID: 5014631.
Copy Download .nbib Format: NLM
[Current problems of drug treatment in nephrology].

Terapevticheskii arkhiv

Mukhin NA, Nikolaev AIu, Tareeva IE.
PMID: 2686072
Ter Arkh. 1989;61(8):3-6.

No abstract available.

Cite
Mukhin NA, Nikolaev AIu, Tareeva IE. Aktual'nye voprosy lekarstvennogo lecheniia v nefrologii. [Current problems of drug treatment in nephrology]. Ter Arkh. 1989;61(8):3-6
Mukhin, N. A., Nikolaev, A. I. u., & Tareeva, I. E. (1989). Aktual'nye voprosy lekarstvennogo lecheniia v nefrologii. [Current problems of drug treatment in nephrology]. Terapevticheskii arkhiv, 61(8), 3-6.
Mukhin, N A, et al. "Aktual'nye voprosy lekarstvennogo lecheniia v nefrologii." [Current problems of drug treatment in nephrology]. Terapevticheskii arkhiv vol. 61,8 (1989): 3-6.
Mukhin NA, Nikolaev AIu, Tareeva IE. Aktual'nye voprosy lekarstvennogo lecheniia v nefrologii. [Current problems of drug treatment in nephrology]. Ter Arkh. 1989;61(8):3-6. Russian. PMID: 2686072.
Copy Download .nbib Format: NLM
[Pathogenesis, diagnosis and therapy of chronic kidney diseases].

Der Landarzt

Kopp H.
PMID: 5712705
Landarzt. 1968 Oct 20;44(29):1397-404.

No abstract available.

Cite
Kopp H. Pathogenese, Diagnostik und Therapie chronischer Nierenkrankheiten. [Pathogenesis, diagnosis and therapy of chronic kidney diseases]. Landarzt. 1968;44(29):1397-404
Kopp, H. (1968). Pathogenese, Diagnostik und Therapie chronischer Nierenkrankheiten. [Pathogenesis, diagnosis and therapy of chronic kidney diseases]. Der Landarzt, 44(29), 1397-404.
Kopp, H. "Pathogenese, Diagnostik und Therapie chronischer Nierenkrankheiten." [Pathogenesis, diagnosis and therapy of chronic kidney diseases]. Der Landarzt vol. 44,29 (1968): 1397-404.
Kopp H. Pathogenese, Diagnostik und Therapie chronischer Nierenkrankheiten. [Pathogenesis, diagnosis and therapy of chronic kidney diseases]. Landarzt. 1968 Oct 20;44(29):1397-404. German. PMID: 5712705.
Copy Download .nbib Format: NLM
Translating immune targets into treatments for kidney disease.

Nature reviews. Nephrology

[No authors listed]
PMID: 26983901
Nat Rev Nephrol. 2016 Apr;12(4):193. doi: 10.1038/nrneph.2016.33.

No abstract available.

Cite
Translating immune targets into treatments for kidney disease. Nat Rev Nephrol. 2016;12(4):193doi: 10.1038/nrneph.2016.33.
(2016). Translating immune targets into treatments for kidney disease. Nature reviews. Nephrology, 12(4), 193. https://doi.org/10.1038/nrneph.2016.33
"Translating immune targets into treatments for kidney disease." Nature reviews. Nephrology vol. 12,4 (2016): 193. doi: https://doi.org/10.1038/nrneph.2016.33
Translating immune targets into treatments for kidney disease. Nat Rev Nephrol. 2016 Apr;12(4):193. doi: 10.1038/nrneph.2016.33. PMID: 26983901.
Copy Download .nbib Format: NLM
Understanding the nature of renal disease progression.

Kidney international

Remuzzi G, Ruggenenti P, Benigni A.
PMID: 8995712
Kidney Int. 1997 Jan;51(1):2-15. doi: 10.1038/ki.1997.2.
Free Article

Animal and human proteinuric glomerulopathies evolve to terminal renal failure by a process leading to progressive parenchymal damage, which appears to be relatively independent of the initial insult. Despite the fact that the mechanism(s) leading to renal disease progression...

Cite
Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51(1):2-15doi: 10.1038/ki.1997.2.
Remuzzi, G., Ruggenenti, P., & Benigni, A. (1997). Understanding the nature of renal disease progression. Kidney international, 51(1), 2-15. https://doi.org/10.1038/ki.1997.2
Remuzzi, G, et al. "Understanding the nature of renal disease progression." Kidney international vol. 51,1 (1997): 2-15. doi: https://doi.org/10.1038/ki.1997.2
Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997 Jan;51(1):2-15. doi: 10.1038/ki.1997.2. PMID: 8995712.
Copy Download .nbib Format: NLM
Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions.

Journal of controlled release : official journal of the Controlled Release Society

Huang Y, Wang J, Jiang K, Chung EJ.
PMID: 33892054
J Control Release. 2021 Jun 10;334:127-137. doi: 10.1016/j.jconrel.2021.04.016. Epub 2021 Apr 20.

Kidney-targeted nanoparticles have become of recent interest due to their potential to deliver drugs directly to diseased tissue, decrease off-target adverse effects, and increase overall tolerability to patients with chronic kidney disease that require lifelong drug exposure. Given the...

Cite
Huang Y, Wang J, Jiang K, et al. Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions. J Control Release. 2021;334:127-137doi: 10.1016/j.jconrel.2021.04.016.
Huang, Y., Wang, J., Jiang, K., & Chung, E. J. (2021). Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions. Journal of controlled release : official journal of the Controlled Release Society, 334127-137. https://doi.org/10.1016/j.jconrel.2021.04.016
Huang, Yi, et al. "Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions." Journal of controlled release : official journal of the Controlled Release Society vol. 334 (2021): 127-137. doi: https://doi.org/10.1016/j.jconrel.2021.04.016
Huang Y, Wang J, Jiang K, Chung EJ. Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions. J Control Release. 2021 Jun 10;334:127-137. doi: 10.1016/j.jconrel.2021.04.016. Epub 2021 Apr 20. PMID: 33892054; PMCID: PMC8192458.
Copy Download .nbib Format: NLM
International trials and pediatric nephrology.

The New England journal of medicine

[No authors listed]
PMID: 366404
N Engl J Med. 1979 Feb 01;300(5):254-5. doi: 10.1056/NEJM197902013000511.

No abstract available.

Cite
International trials and pediatric nephrology. N Engl J Med. 1979;300(5):254-5doi: 10.1056/NEJM197902013000511.
(1979). International trials and pediatric nephrology. The New England journal of medicine, 300(5), 254-5. https://doi.org/10.1056/NEJM197902013000511
"International trials and pediatric nephrology." The New England journal of medicine vol. 300,5 (1979): 254-5. doi: https://doi.org/10.1056/NEJM197902013000511
International trials and pediatric nephrology. N Engl J Med. 1979 Feb 01;300(5):254-5. doi: 10.1056/NEJM197902013000511. PMID: 366404.
Copy Download .nbib Format: NLM
Developing guidelines for chronic kidney disease: we should include all of the outcomes.

Annals of internal medicine

Uhlig K, Levey AS.
PMID: 22508736
Ann Intern Med. 2012 Apr 17;156(8):599-601. doi: 10.7326/0003-4819-156-8-201204170-00009.

No abstract available.

Cite
Uhlig K, Levey AS. Developing guidelines for chronic kidney disease: we should include all of the outcomes. Ann Intern Med. 2012;156(8):599-601doi: 10.7326/0003-4819-156-8-201204170-00009.
Uhlig, K., & Levey, A. S. (2012). Developing guidelines for chronic kidney disease: we should include all of the outcomes. Annals of internal medicine, 156(8), 599-601. https://doi.org/10.7326/0003-4819-156-8-201204170-00009
Uhlig, Katrin, and Levey, Andrew S. "Developing guidelines for chronic kidney disease: we should include all of the outcomes." Annals of internal medicine vol. 156,8 (2012): 599-601. doi: https://doi.org/10.7326/0003-4819-156-8-201204170-00009
Uhlig K, Levey AS. Developing guidelines for chronic kidney disease: we should include all of the outcomes. Ann Intern Med. 2012 Apr 17;156(8):599-601. doi: 10.7326/0003-4819-156-8-201204170-00009. PMID: 22508736.
Copy Download .nbib Format: NLM
The Progression of Kidney Disease in Patients with HIV.

Nephrology nursing journal : journal of the American Nephrology Nurses' Association

Brown JS.
PMID: 26207289
Nephrol Nurs J. 2015 May-Jun;42(3):285-7.

No abstract available.

Cite
Brown JS. The Progression of Kidney Disease in Patients with HIV. Nephrol Nurs J. 2015;42(3):285-7
Brown, J. S. (2015). The Progression of Kidney Disease in Patients with HIV. Nephrology nursing journal : journal of the American Nephrology Nurses' Association, 42(3), 285-7.
Brown, Jami Smith. "The Progression of Kidney Disease in Patients with HIV." Nephrology nursing journal : journal of the American Nephrology Nurses' Association vol. 42,3 (2015): 285-7.
Brown JS. The Progression of Kidney Disease in Patients with HIV. Nephrol Nurs J. 2015 May-Jun;42(3):285-7. PMID: 26207289.
Copy Download .nbib Format: NLM
SGLT2 inhibitors may offer benefit beyond diabetes.

Nature reviews. Nephrology

Kang A, Jardine MJ.
PMID: 33361782
Nat Rev Nephrol. 2021 Feb;17(2):83-84. doi: 10.1038/s41581-020-00391-2.

No abstract available.

Cite
Kang A, Jardine MJ. SGLT2 inhibitors may offer benefit beyond diabetes. Nat Rev Nephrol. 2021;17(2):83-84doi: 10.1038/s41581-020-00391-2.
Kang, A., & Jardine, M. J. (2021). SGLT2 inhibitors may offer benefit beyond diabetes. Nature reviews. Nephrology, 17(2), 83-84. https://doi.org/10.1038/s41581-020-00391-2
Kang, Amy, and Jardine, Meg J. "SGLT2 inhibitors may offer benefit beyond diabetes." Nature reviews. Nephrology vol. 17,2 (2021): 83-84. doi: https://doi.org/10.1038/s41581-020-00391-2
Kang A, Jardine MJ. SGLT2 inhibitors may offer benefit beyond diabetes. Nat Rev Nephrol. 2021 Feb;17(2):83-84. doi: 10.1038/s41581-020-00391-2. PMID: 33361782.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries